Get the Stockscreener App
84.84
0.56%
-0.48
After Hours:
85.00
0.16
+0.19%
Edwards Lifesciences Corp stock is traded at $84.84, with a volume of 3.60M.
It is down -0.56% in the last 24 hours and up +0.12% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$85.32
Open:
$85.76
24h Volume:
3.60M
Relative Volume:
0.81
Market Cap:
$49.23B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
36.12
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
+1.10%
1M Performance:
+0.12%
6M Performance:
+15.79%
1Y Performance:
+14.46%
1-Day Range:
$84.67
$86.19
1-Week Range:
$81.85
$86.19
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.84 | 49.51B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
126.71 | 220.59B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.48 | 137.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
352.58 | 134.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.30 | 125.28B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Canaccord Genuity Lowers Price Target for Edwards Lifesciences (EW) to $87 | EW Stock News - GuruFocus
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider - GlobeNewswire Inc.
Edwards Lifesciences (EW): Reassessing Valuation After Strong Sales Growth and Upgraded Guidance - simplywall.st
Edwards seeks a TAVR two-fer in Medicare coverage petition - BioWorld MedTech
Transcatheter heart valves market to enjoy solid growth - MassDevice
Baird Trims Price Target on Edwards Lifesciences to $87 From $88, Maintains Neutral Rating - marketscreener.com
CMS accepts Edwards request for national TAVR coverage review - MassDevice
Edwards Lifesciences (EW): Analyst Rating Maintained, Price Targ - GuruFocus
BTIG reiterates Buy rating on Edwards Lifesciences stock amid TAVR review - Investing.com
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences Resolves $140 Million Harpoon Medical Case - Bloomberg Law News
Edwards Lifesciences Completes Key Study on SAPIEN XT THV - TipRanks
Squarepoint Ops LLC Acquires 50,924 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
Is There Now An Opportunity In Edwards Lifesciences Corporation (NYSE:EW)? - Yahoo Finance
Holocene Advisors LP Buys 1,223,460 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
934,449 Shares in Edwards Lifesciences Corporation $EW Bought by Hudson Bay Capital Management LP - MarketBeat
Hudson Bay Capital Management LP Invests $73.08 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Liontrust Investment Partners LLP Has $112.04 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 11,386 Shares - MarketBeat
Elevatus Welath Management Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Bellevue Group AG Sells 82,892 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Banque Transatlantique SA Purchases 24,575 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Heisz Stone Sells Shares of Edwards Lifesciences C - GuruFocus
VP Bobo Jr Sells 11,386 ($953.7K) Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
Edwards Lifesciences (EW) executive reports stock sales and 7,100-share gift - Stock Titan
Edwards Lifesciences (EW) officer exercises options and sells 1,019 shares - Stock Titan
Edwards Lifesciences (EW) director reports sale of 2,615 shares at $83.41 - Stock Titan
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Shareholder Bobo Donald E Jr Fam Trust Files To Sell 5,900 Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
EW (NYSE: EW) Rule 144 filing details planned sale of 5,900 shares - Stock Titan
Edwards Lifesciences (EW) insider plans Rule 144 sale of 2,615 common shares - Stock Titan
Edwards Lifesciences (NYSE: EW) insider files Form 144 to sell 5,487 shares - Stock Titan
Edwards Lifesciences Reports Strong Earnings and Growth - MSN
Nebula Research & Development LLC Sells 16,819 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Purchased by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main - MarketBeat
Edwards Lifesciences (NYSE:EW) VP Sells 11,340 Shares - MarketBeat
Edwards Lifesciences (EW) executive reports sale of 2,000 shares on Form 4 - Stock Titan
Edwards Lifesciences (NYSE: EW) investor files Rule 144 to sell 2,000 shares - Stock Titan
Edwards Lifesciences Corporation $EW Shares Sold by Glenview Trust co - MarketBeat
Citigroup Adjusts Edwards Lifesciences Price Target to $101 From $96, Maintains Buy Rating - marketscreener.com
State Street Corp Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Insider Sold Shares Worth $2,153,373, According to a Recent SEC Filing - marketscreener.com
Daiwa Securities Group Inc. Acquires 24,475 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Bank of Nova Scotia Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Transcript : Edwards Lifesciences CorporationAnalyst/Investor Day - marketscreener.com
Edwards Lifesciences Corp Officer Sells Shares - TradingView — Track All Markets
VP Bobo Jr Sells 11,340 ($950.6K) Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
Edwards Lifesciences officer exercises 11,340 options and sells shares | EW SEC FilingForm 4 - Stock Titan
Edwards Lifesciences (EW) CEO reports option exercise and stock sales in Form 4 - Stock Titan
VP Bobo Jr Files To Sell 11,340 Of Edwards Lifesciences Corp [EW] - TradingView — Track All Markets
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):